Your browser doesn't support javascript.
loading
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Herpers, Bram; Eppink, Berina; James, Mark I; Cortina, Carme; Cañellas-Socias, Adrià; Boj, Sylvia F; Hernando-Momblona, Xavier; Glodzik, Dominik; Roovers, Rob C; van de Wetering, Marc; Bartelink-Clements, Carina; Zondag-van der Zande, Vanessa; Mateos, Jara García; Yan, Kuan; Salinaro, Lucia; Basmeleh, Abdul; Fatrai, Szabolcs; Maussang, David; Lammerts van Bueren, Jeroen J; Chicote, Irene; Serna, Garazi; Cabellos, Laia; Ramírez, Lorena; Nuciforo, Paolo; Salazar, Ramon; Santos, Cristina; Villanueva, Alberto; Stephan-Otto Attolini, Camille; Sancho, Elena; Palmer, Hector G; Tabernero, Josep; Stratton, Michael R; de Kruif, John; Logtenberg, Ton; Clevers, Hans; Price, Leo S; Vries, Robert G J; Batlle, Eduard; Throsby, Mark.
Afiliação
  • Herpers B; OcellO BV, Leiden, The Netherlands.
  • Eppink B; Crown Bioscience Netherlands BV, Leiden, The Netherlands.
  • James MI; Merus NV, Utrecht, The Netherlands.
  • Cortina C; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Cañellas-Socias A; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Boj SF; CIBERONC, Madrid, Spain.
  • Hernando-Momblona X; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Glodzik D; CIBERONC, Madrid, Spain.
  • Roovers RC; Hubrecht Organoid Technology (HUB), Utrecht, the Netherlands.
  • van de Wetering M; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Bartelink-Clements C; CIBERONC, Madrid, Spain.
  • Zondag-van der Zande V; Wellcome Sanger Institute, Hinxton, UK.
  • Mateos JG; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Yan K; Merus NV, Utrecht, The Netherlands.
  • Salinaro L; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Basmeleh A; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, Utrecht, the Netherlands.
  • Fatrai S; Oncode Institute, Hubrecht Institute, Utrecht, the Netherlands.
  • Maussang D; Merus NV, Utrecht, The Netherlands.
  • Lammerts van Bueren JJ; Merus NV, Utrecht, The Netherlands.
  • Chicote I; OcellO BV, Leiden, The Netherlands.
  • Serna G; Crown Bioscience Netherlands BV, Leiden, The Netherlands.
  • Cabellos L; OcellO BV, Leiden, The Netherlands.
  • Ramírez L; Crown Bioscience Netherlands BV, Leiden, The Netherlands.
  • Nuciforo P; OcellO BV, Leiden, The Netherlands.
  • Salazar R; Merus NV, Utrecht, The Netherlands.
  • Santos C; Merus NV, Utrecht, The Netherlands.
  • Villanueva A; Merus NV, Utrecht, The Netherlands.
  • Stephan-Otto Attolini C; Merus NV, Utrecht, The Netherlands.
  • Sancho E; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Palmer HG; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Tabernero J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Stratton MR; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain.
  • de Kruif J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Logtenberg T; Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain.
  • Clevers H; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Price LS; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Vries RGJ; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Batlle E; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
  • Throsby M; Xenopat SL, Parc Cientific de Barcelona (PCB), Barcelona, Spain.
Nat Cancer ; 3(4): 418-436, 2022 04.
Article em En | MEDLINE | ID: mdl-35469014
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Neoplasias Epiteliais e Glandulares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Neoplasias Epiteliais e Glandulares Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article